Posted on 12/05/2009 in Pharmaceutical Company Product News Gilead Sciences has published data from a phase III clinical trial investigating darusentan, which is an oral endothelin receptor antagonist (ERA) aimed for a once-daily dosage.
The drug is designed to be an add-on treatment for resistant hypertension and the study showed a "significant" reduction in the blood pressure of patients.
A total of 379 people took part in the double-blind placebo-controlled trial.
Dr Michael A Weber, lead author of the research and professor of medicine at the State University of New York Downstate Medical College in Brooklyn, US, said the failure to control blood pressure has various life-threatening cardiovascular conditions associated with it and that is why new therapeutic approaches have to be looked at.
"These data are important because they showed meaningful reductions in blood pressure when darusentan was added to existing antihypertensive regimens," he explained.
Gilead Sciences has operated since 1987 and is headquartered in California's Foster City with more than 4,000 employees.
Other news stories from 12/05/2009
Read more in the Zenopa News Archive
How this news is generated
|
